- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07798154
Effect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients (SBA-APRV)
A Randomized Controlled Trial Of The Effect Of Spontaneous Breathing In APRV Mode On Respiratory Physiology In Patients With Acute Respiratory Distress Syndrome
연구 개요
상태
상세 설명
Acute respiratory distress syndrome (ARDS) is a life-threatening critical respiratory illness characterized by heterogeneous pulmonary injury and severe ventilation-perfusion mismatch. Airway Pressure Release Ventilation (APRV) permits spontaneous breathing throughout the whole respiratory cycle, which may improve regional ventilation-perfusion matching and hemodynamic status. Nevertheless, excessive spontaneous breathing effort may trigger pendelluft phenomenon, augment regional lung strain and precipitate patient-self-inflicted lung injury (P-SILI). To date, the safe intensity range of spontaneous breathing during APRV for moderate-to-severe ARDS patients has not been well defined.
This single-center, randomized 3-period crossover self-controlled physiological trial enrolls ICU adult patients aged 18-80 years, diagnosed with moderate-to-severe ARDS (PaO₂/FiO₂ ≤ 150 mmHg) within 48-hours of invasive mechanical ventilation. After written informed consent obtained from legal surrogates, subjects will first receive a 60-minute baseline ventilation period following ARDSnet low-tidal-volume pressure-control ventilation strategy under deep sedation without spontaneous breathing. Subsequently, every participant will undergo three APRV intervention states in computer-generated random order: Condition A: APRV with low-intensity spontaneous breathing (spontaneous-contributed minute ventilation 10%-30%); Condition B: APRV with high-intensity spontaneous breathing (31%-50%); Condition C: APRV with fully suppressed spontaneous breathing via deep sedation (RASS -4 to -5). Each intervention maintains target spontaneous-breathing intensity for 30-minute stabilization before data collection. A mandatory 30-minute wash-out phase will be implemented between successive interventions to revert subjects back to baseline pressure-control ventilation and sedation status.
Primary endpoint is the comparison of ventilation-perfusion mismatch percentage (mismatch%, calculated as sum of dead-space fraction and shunt fraction) among three states measured by bedside EIT. Secondary endpoints contain multiple EIT quantitative indices, respiratory mechanics parameters (including esophageal-pressure-derived transpulmonary pressure), hemodynamic and right-ventricular function, diaphragmatic ultrasound indices, arterial blood gas variables. Adverse events related to respiratory, circulatory and operational procedures are closely monitored as safety outcomes.
Planned sample size is 14-16 enrolled participants to achieve 12 evaluable subjects completing all three intervention sequences considering dropout rate. All ventilator and sedation modifications are short-term and reversible; standard clinical therapeutic regimens will not be altered except for study-related procedures. After finishing all three intervention periods, ventilator and sedation settings will be returned to clinical team's discretion. Linear mixed-effect models will be applied for statistical analysis of crossover-design data.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Xiaojing Zou
- 전화번호: +86-27-85351606
- 이메일: 249126734@qq.com
연구 장소
-
-
Hubei
-
Wuhan, Hubei, 중국, 430022
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
연락하다:
- Xiaojing Zou
- 전화번호: +86-27-85351606
- 이메일: 249126734@qq.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
1. Age ≥18 and ≤80 years old. 2. Diagnosed with moderate-to-severe ARDS according to the 2023 global ARDS definition.
3. Within 48 hours of invasive mechanical ventilation. After 1-hour low-tidal-volume pressure-controlled ventilation following ARDSnet strategy, arterial blood gas shows PaO₂/FiO₂ ≤ 150 mmHg.
4. Written informed consent is obtained from the patient or their legal surrogate decision-maker after full explanation of the study by the principal investigator or authorized study physician.
Exclusion Criteria:
1. Refractory shock defined as persistent hyperlactatemia and/or prolonged capillary refill time, fluid-resistant, requiring norepinephrine ≥ 0.5 μg/kg/min.
2. Severe chronic medical conditions severely affecting cardiopulmonary function: severe chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right-heart failure, pulmonary hypertension, or severe arrhythmia.
3. Radiologically confirmed bronchopleural fistula, status post lobectomy, or other major thoracic surgery.
4. Contraindications to electrical impedance tomography (EIT): extensive chest skin injury or infection, implanted cardiac pacemaker or defibrillator, etc.
5. Contraindications for esophageal manometry placement: esophageal obstruction, perforation, severe esophageal varices, etc.
6. Diaphragmatic hernia, severe chest wall deformity, or significant pulmonary bullae.
7. Significant coagulation abnormalities (PT or APTT prolonged ≥2 times upper limit of normal, or INR>2.0) with active bleeding risk.
8. Severe intracranial hypertension (>20 mmHg), severe traumatic brain injury (GCS ≤8), or neuromuscular disorders.
9. Pregnant or breastfeeding women. 10. Patients already receiving ECMO therapy. 11. Expected survival time <24 hours judged by attending physician. 12. Body mass index (BMI) >35 kg/m². 13. Previously enrolled in this study or participating in other interventional clinical trials.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
A stabilization period of 30 minutes is performed before data collection
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
30-minute stabilization before outcome measurement.
|
|
실험적: High-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
30-minute stabilization before outcome measurement.
|
|
실험적: Fully suppressed spontaneous breathing under APRV
APRV ventilation with spontaneous breathing completely suppressed by deep sedation (RASS-4 to -5).
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous breathing fully suppressed by deep sedation (RASS-4 to -5).
30-minute stabilization before outcome measurement.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Ventilation-perfusion mismatch percentage (Mismatch%)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilation-perfusion mismatch percentage (Mismatch%), calculated as the sum of dead-space percentage and shunt percentage measured by electrical impedance tomography (EIT).
A composite index reflecting overall ventilation-perfusion mismatch, assessed at baseline and under three APRV experimental conditions.
Unit: %
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Match percentage(match%)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Match percentage derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Pendelluft amplitude
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pendelluft amplitude derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dead-space percentage
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dead-space percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Shunt percentage
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Intrapulmonary shunt percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Global inhomogeneity index (GI)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
Global inhomogeneity index (GI) derived from electrical impedance tomography (EIT).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
|
Center of ventilation (CoV)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Center of ventilation (CoV) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tidal recruitment-derecruitment
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tidal recruitment-derecruitment (Tidal R/D) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Ventilation distribution
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional ventilation distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Perfusion distribution
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional pulmonary perfusion distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Peak airway pressure (Ppeak)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway peak pressure (Ppeak) measured by mechanical ventilator, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Plateau pressure (Pplat)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway plateau pressure (Pplat) obtained from end-inspiratory hold maneuver, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Driving pressure (ΔP)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Driving pressure (ΔP) derived from mechanical ventilator measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Static respiratory system compliance (Cstat)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Static respiratory system compliance (Cstat), assessed at baseline and under three APRV experimental conditions.
Unit: mL/cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory esophageal pressure (PesI)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory esophageal pressure (PesI) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory esophageal pressure (PesE)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory esophageal pressure (PesE) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure swing (ΔPes)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure swing (ΔPes) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory transpulmonary pressure (PtpI)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory transpulmonary pressure (PtpI) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Transpulmonary driving pressure (ΔPtp)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Transpulmonary driving pressure (ΔPtp) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory transpulmonary pressure (PtpE)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory transpulmonary pressure (PtpE) derived from airway and esophageal pressure, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure-time product per minute (PTPes/min)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure-time product per minute (PTPes/min) read directly from the ventilator interface.
Unit: cmH₂O·s/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dynamic transpulmonary driving pressure (ΔPL,dyn)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Dynamic transpulmonary driving pressure (ΔPL,dyn) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O.
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Inspiratory muscle pressure (Pmus)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Inspiratory muscle pressure (Pmus) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
End-expiratory occlusion pressure (ΔPocc)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
End-expiratory occlusion pressure (ΔPocc) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Airway occlusion pressure (P0.1)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Airway occlusion pressure (P0.1) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Muscular pressure index (PMI)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Muscular pressure index (PMI) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Negative inspiratory force (NIF)
기간: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Negative inspiratory force (NIF) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Heart rate
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Heart rate from continuous bedside monitoring, assessed at baseline and under three APRV experimental conditions.
Unit: beats per minute.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Mean arterial pressure (MAP)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mean arterial pressure (MAP) measured via invasive arterial catheter, assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Vasopressor dosage (μg/kg/min)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dosage of vasoactive medications, assessed at baseline and under three APRV experimental conditions.
Unit: μg/kg/min
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Central venous pressure (CVP)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Central venous pressure (CVP), assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Right-ventricular fractional area change
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Right-ventricular fractional area change measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Velocity-time-integral (VTI)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: cm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tricuspid annular plane systolic excursion (TAPSE)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tricuspid annular plane systolic excursion (TAPSE) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Cardiac output (CO)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Cardiac output (CO) calculated from velocity-time integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Stroke volume (SV)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Stroke volume (SV) calculated from velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Diaphragm displacement
기간: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm displacement measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: mm.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Diaphragm thickening fraction
기간: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm thickening fraction measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Lung 12-zone ultrasound score
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Lung ultrasound score based on 12-zone lung ultrasound assessment, assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) pixel count
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung overdistension (OD), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) proportion
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung overdistension (OD) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) pixel count
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung recruitment (CR), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) proportion
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung recruitment (CR) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) pixel count
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung atelectasis (AT), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) proportion
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung atelectasis (AT) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence and severity of adverse events
기간: During each APRV experimental intervention period
|
Incidence and severity of adverse events during study interventions, focusing on respiratory events, circulatory events and procedure-related adverse events.
Unit: unitless.
|
During each APRV experimental intervention period
|
|
Rate of premature intervention discontinuation for safety concerns
기간: During each APRV experimental intervention period
|
Rate of premature discontinuation of study interventions due to safety-related reasons.
Unit: %.
|
During each APRV experimental intervention period
|
|
Inspired oxygen fraction (FiO₂)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Set inspired oxygen fraction, obtained directly from ventilator readings, recorded at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial pH
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial blood pH measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of oxygen (PaO₂)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of oxygen measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of carbon dioxide (PaCO₂)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of carbon dioxide measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial oxygen saturation (SaO₂)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial oxygen saturation measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Bicarbonate (HCO₃-)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Serum bicarbonate (HCO₃-) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Base excess (BE)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Base excess (BE) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial lactate (Lac)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial lactate (Lac) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
PaO₂/FiO₂ ratio
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
PaO₂/FiO₂ ratio calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Alveolar-arterial oxygen difference (A-aDO₂)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Alveolar-arterial oxygen difference calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Correlation analysis among multiple respiratory-hemodynamic-diaphragm parameters
기간: Corresponding study time points
|
Explore the correlations among EIT parameters, respiratory mechanics, blood gas analysis, hemodynamics and diaphragm function across three study conditions.
|
Corresponding study time points
|
|
Ventilatory ratio (VR)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilatory ratio (VR), a calculated index reflecting pulmonary dead-space and lung injury severity, is computed from minute ventilation and arterial CO₂ values assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Expired tidal volume (VTe)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Expired tidal volume assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total respiratory rate
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total respiratory rate assessed at baseline and under three APRV experimental conditions.
Unit: breaths/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total minute ventilation
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total minute ventilation assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Spontaneous minute ventilation
기간: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Spontaneous component of minute ventilation assessed under two APRV experimental conditions only when spontaneous breathing was present, derived directly from ventilator readings.
Unit: L/min.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Proportion of spontaneous minute ventilation
기간: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Proportion of spontaneous minute ventilation relative to total minute ventilation, calculated under two APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Mechanical power (MP)
기간: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mechanical power of ventilation as an indicator of ventilator-induced lung injury (VILI) risk, obtained directly from ventilator readings at baseline and under three APRV experimental conditions.
Unit: J/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: xiaojing zou, MD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- PROTO-APRV-2026-01
- MR-42-26-065895 (기타 식별자: National Medical Research Registration and Filing Information System of China)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .